Toll-like receptor genetic variants and colorectal cancer

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Weber, Alexander N R ^a   Försti, Asta ^b,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Biomarker; Colorectal cancer; Flagellin; Single nucleotide polymorphism; Toll like receptors

Indexed keywords

BIOLOGICAL MARKER; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CYTOKINE RESPONSE; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INFECTION; INTESTINE FLORA; MICROBIAL COLONIZATION; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; TOLL LIKE RECEPTOR GENE;

EID: 84899092476     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27763     Document Type: Article

References (10)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi. org/10.3322/caac.20107.
2. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 2010; 10:131-44; PMID:20098461; http://dx.doi. org/10.1038/nri2707.
3. Pagès F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol 2008; 84:981-7; PMID:18559950; http://dx.doi.org/10.1189/jlb.1107773.
4. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637-50; PMID:21616434; http://dx.doi.org/10.1016/j. immuni.2011.05.006.
5. Klimosch SN, Försti A, Eckert J, Knezevic J, Bevier M, von Schönfels W, Heits N, Walter J, Hinz S, Lascorz J, et al. Functional TLR5 genetic variants affect human colorectal cancer survival. Cancer Res 2013; 73:7232-42; PMID:24154872; http://dx.doi. org/10.1158/0008-5472.CAN-13-1746.
6. Castro FA, Försti A, Buch S, Kalthoff H, Krauss C, Bauer M, Egberts J, Schniewind B, Broering DC, Schreiber S, et al. TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer 2011; 47:1203-10; PMID:21239167; http://dx.doi.org/10.1016/j. ejca.2010.12.011.
7. Waldner MJ, Foersch S, Neurath MF. Interleukin-6-a key regulator of colorectal cancer development. Int J Biol Sci 2012; 8:1248-53; PMID:23136553; http://dx.doi.org/10.7150/ijbs.4614.
8. Grossman SR, Andersen KG, Shlyakhter I, Tabrizi S, Winnicki S, Yen A, Park DJ, Griesemer D, Karlsson EK, Wong SH, et al.; 1000 Genomes Project. Identifying recent adaptations in large-scale genomic data. Cell 2013; 152:703-13; PMID:23415221; http://dx.doi.org/10.1016/j.cell.2013.01.035.
9. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328:228-31; PMID:20203013; http://dx.doi.org/10.1126/science.1179721.
10. Brenner H, Altenhofen L, Hoffmeister M. Eight years of colonoscopic bowel cancer screening in Germany: initial findings and projections. Dtsch Arztebl Int 2010; 107:753-9; PMID:21085544.